US Proposes Japanese Deregulation Talks

18 May 1997

The USA has proposed that vice-ministerial negotiations be set up withJapan concerning deregulation, with pharmaceuticals as one of four initial focus areas (the others are financial services, telecommunications and housing construction). It also suggests a bilateral working-level group to decide which areas might be upgraded for negotiations at the vice-ministerial forum.

The USA has expressed discontent with the current method of talks with Japan, which it sees as failing to address major sectoral deregulation. Sectoral talks are more effective, says US Trade Representative Charlene Barshefsky.

On Japan's competition and administrative reform policies, Washington wants to continue the current method of the USA periodically commenting on Japan's initiatives and requesting extra measures through a bilateral working group set up under the 1993 framework trade agreement, sources told the Kyodo news service.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight